Up a level |
Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J ORCID: 0000-0001-5608-001X, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L et al (show 38 more authors)
(2022)
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
LANCET, 399 (10323).
pp. 447-460.
James, Nicholas D, Clarke, Noel W, Cook, Adrian, Ali, Adnan, Hoyle, Alex P, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William R, Dearnaley, David P et al (show 46 more authors)
(2022)
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
INTERNATIONAL JOURNAL OF CANCER, 151 (3).
pp. 422-434.
Stainthorpe, Angela, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Dundar, Yenal, McEntee, Joanne and Syndikus, Isabel
(2020)
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
PHARMACOECONOMICS-OPEN, 4 (4).
pp. 563-574.